179 related articles for article (PubMed ID: 38917394)
1. Emerging Oral Pharmaceuticals for Dry Age-Related Macular Degeneration: Mechanism of Action, Current Clinical Status, and Future Directions.
DeBoer CMT; Rasmussen DK; Franco JA; Mahajan VB
Ophthalmic Surg Lasers Imaging Retina; 2024 Jun; ():1-7. PubMed ID: 38917394
[TBL] [Abstract][Full Text] [Related]
2. Treatment of dry age-related macular degeneration: A review.
Girgis S; Lee LR
Clin Exp Ophthalmol; 2023 Nov; 51(8):835-852. PubMed ID: 37737509
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
Nebbioso M; Lambiase A; Cerini A; Limoli PG; La Cava M; Greco A
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987401
[TBL] [Abstract][Full Text] [Related]
4. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions.
Cabral de Guimaraes TA; Daich Varela M; Georgiou M; Michaelides M
Br J Ophthalmol; 2022 Mar; 106(3):297-304. PubMed ID: 33741584
[TBL] [Abstract][Full Text] [Related]
5. Complement inhibitors for age-related macular degeneration.
Tzoumas N; Riding G; Williams MA; Steel DH
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009300. PubMed ID: 37314061
[TBL] [Abstract][Full Text] [Related]
6. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
Yeong JL; Loveman E; Colquitt JL; Royle P; Waugh N; Lois N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013154. PubMed ID: 33331670
[TBL] [Abstract][Full Text] [Related]
7. Treatment for dry age-related macular degeneration: where we stand in 2024.
Wheeler S; Mahmoudzadeh R; Randolph J
Curr Opin Ophthalmol; 2024 Jun; ():. PubMed ID: 38869976
[TBL] [Abstract][Full Text] [Related]
8. Age-related macular degeneration therapy: a review.
Ammar MJ; Hsu J; Chiang A; Ho AC; Regillo CD
Curr Opin Ophthalmol; 2020 May; 31(3):215-221. PubMed ID: 32205470
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the management of dry age-related macular degeneration: A review.
Bandello F; Sacconi R; Querques L; Corbelli E; Cicinelli MV; Querques G
F1000Res; 2017; 6():245. PubMed ID: 28529701
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy.
Kim JB; Lad EM
Drugs Aging; 2021 Jan; 38(1):17-27. PubMed ID: 33355716
[TBL] [Abstract][Full Text] [Related]
11. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
Tolentino MJ; Dennrick A; John E; Tolentino MS
Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
[TBL] [Abstract][Full Text] [Related]
12. The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials.
Kumar-Singh R
Exp Eye Res; 2019 Jul; 184():266-277. PubMed ID: 31082363
[TBL] [Abstract][Full Text] [Related]
13. Using Advanced Bioinformatics Tools to Identify Novel Therapeutic Candidates for Age-Related Macular Degeneration.
Nadeem U; Xie B; Xie EF; D'Souza M; Dao D; Sulakhe D; Skondra D
Transl Vis Sci Technol; 2022 Aug; 11(8):10. PubMed ID: 35972434
[TBL] [Abstract][Full Text] [Related]
14. Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.
Khan H; Aziz AA; Sulahria H; Khan H; Ahmed A; Choudhry N; Narayanan R; Danzig C; Khanani AM
Clin Ophthalmol; 2023; 17():321-327. PubMed ID: 36741078
[TBL] [Abstract][Full Text] [Related]
15. A Clinical and Preclinical Assessment of Clinical Trials for Dry Age-Related Macular Degeneration.
Abidi M; Karrer E; Csaky K; Handa JT
Ophthalmol Sci; 2022 Dec; 2(4):100213. PubMed ID: 36570624
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Complement Cascade for Treatment of Dry Age-Related Macular Degeneration.
Patel PN; Patel PA; Land MR; Bakerkhatib-Taha I; Ahmed H; Sheth V
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009430
[TBL] [Abstract][Full Text] [Related]
17. Tissue engineering in age-related macular degeneration: a mini-review.
Wu A; Lu R; Lee E
J Biol Eng; 2022 May; 16(1):11. PubMed ID: 35578246
[TBL] [Abstract][Full Text] [Related]
18. Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system.
Bakri SJ; Bektas M; Sharp D; Luo R; Sarda SP; Khan S
J Manag Care Spec Pharm; 2023 May; 29(5-a Suppl):S2-S11. PubMed ID: 37125931
[TBL] [Abstract][Full Text] [Related]
19. Patient acceptability of intravitreal complement inhibitors in geographic atrophy (GA): protocol for a UK-based cross-sectional study.
Dinah C; Enoch J; Ghulakhszian A; Sekhon M; Crabb DP; Taylor DJ
BMJ Open; 2024 Jan; 14(1):e075713. PubMed ID: 38238063
[TBL] [Abstract][Full Text] [Related]
20. Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.
Rothman AL; Beca FA; Tijerina JD; Schuman DM; Parrish RK; Vanner EA; Liu KC
Ophthalmol Glaucoma; 2024; 7(3):260-270. PubMed ID: 38266962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
